LEADER 01040nam a22002531i 4500
001 991001358019707536
005 20031104162435.0
008 040407s1969    uika||||||||||||||||eng  
035   $ab1275805x-39ule_inst
035   $aARCHE-073768$9ExL
040   $aDip.to Scienze Storiche$bita$cA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l.
082 04$a759.5
100 1 $aPanofsky, Erwin$010910
245 10$aProblems in Titian mostly iconographic /$cErwin Panofsky
260   $aLondon :$bPhaidon,$cc1969
300   $aXV, 208 p., [67] c. di tav. :$bill. ;$c28 cm
440  4$aThe Wrightsman lectures / delivered under the auspices of the New York University Institute of Fine Arts
650  4$aTiziano Vecellio
907   $a.b1275805x$b02-04-14$c16-04-04
912   $a991001358019707536
945   $aLE009 LA II D 31$g1$i2009000225626$lle009$o-$pE0.00$q-$rn$so  $t0$u0$v0$w0$x0$y.i13297624$z16-04-04
996   $aProblems in Titian mostly iconographic$9267162
997   $aUNISALENTO
998   $ale009$b16-04-04$cm$da  $e-$feng$guik$h0$i1

LEADER 01698nam  2200349   450 
001 9910688456203321
005 20230630044620.0
035   $a(CKB)5400000000044771
035   $a(NjHacI)995400000000044771
035   $a(EXLCZ)995400000000044771
100   $a20230630d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aAdvances in Precision Medicine Oncology /$fHilal Arnouk, Bassam Hassan, editor
210  1$aLondon :$cIntechOpen,$d2021.
215   $a1 online resource (260 pages)
311   $a1-83968-869-6 
330   $aRecent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects.
606   $aCancer$xTreatment
615  0$aCancer$xTreatment.
676   $a616.99406
702   $aHassan$b Bassam
702   $aArnouk$b Hilal
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688456203321
996   $aAdvances in Precision Medicine Oncology$92828415
997   $aUNINA